SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Elan Corporation, plc (ELN) -- Ignore unavailable to you. Want to Upgrade?


To: IRWIN JAMES FRANKEL who wrote (6261)1/17/2005 10:34:52 PM
From: Biomaven  Read Replies (2) | Respond to of 10345
 
Seems to me (on strictly intuitive grounds) that Rebif will be the big loser. Presumably the reason one would go with Rebif over Avonex in the first place is that one was more concerned with efficacy than convenience given the more frequent Rebif injections. But now Tysabri undercuts that rationale. So wouldn't the Rebif patients logically be prime candidates to jump to Tysabri?

Peter